Edwards Lifesciences

EDWARDS SAPIEN 3 TAVR DELIVERS PROVEN LONG-TERM BENEFITS AND VALVE PERFORMANCE, NEW DATA PRESENTED AT TCT 2025

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years
SUCCESSFUL PATIENT OUTCOMES DEMONSTRATED WITH EDWARDS’ SAPIEN M3 AND EVOQUE SYSTEMS, NEW DATA PRESENTED AT TCT 2025

ENCIRCLE mitral trial achieves primary and secondary endpoints.
EDWARDS TAVR RECEIVES FDA APPROVAL FOR PATIENTS WITH ASYMPTOMATIC SEVERE AORTIC STENOSIS

Transforming Care for Severe AS Patients
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA

EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA
BD Completes Acquisition of Critical Care from Edwards Lifesciences

BD announced it has completed the acquisition of Edwards Lifesciences’ Critical Care product group, which will be renamed…
FIRST ALL-FEMALE TAVI TRIAL SHOWS EXCELLENT OUTCOMES FOR WOMEN RECEIVING EDWARDS VALVES

Edwards Lifesciences announced the results from the RHEIA Trial.
FIVE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR FEMALE AND SMALL ANNULUS PATIENTS WITH EDWARDS TAVR

FIVE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR FEMALE AND SMALL ANNULUS PATIENTS WITH EDWARDS TAVR
Edwards Lifesciences to Sell Critical Care to BD

Agreement strengthens Edwards’ strategy to advance structural heart innovation.
LARGE, REAL-WORLD STUDIES DEMONSTRATE CONTINUED EXCELLENT OUTCOMES FOR PATIENTS RECEIVING EDWARDS SAPIEN TAVR

LARGE, REAL-WORLD STUDIES DEMONSTRATE CONTINUED EXCELLENT OUTCOMES FOR PATIENTS RECEIVING EDWARDS SAPIEN TAVR
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Edwards receives CE mark for tricuspid valve replacement

The company expects to receive U.S. approval late next year.
EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL

Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards’ breakthrough RESILIA tissue…

Call to Action

Experience Seamless Style and Speed

Explore More

EDWARDS SAPIEN 3 TAVR DELIVERS PROVEN LONG-TERM BENEFITS AND VALVE PERFORMANCE, NEW DATA PRESENTED AT TCT 2025

SUCCESSFUL PATIENT OUTCOMES DEMONSTRATED WITH EDWARDS’ SAPIEN M3 AND EVOQUE SYSTEMS, NEW DATA PRESENTED AT TCT 2025

EDWARDS TAVR RECEIVES FDA APPROVAL FOR PATIENTS WITH ASYMPTOMATIC SEVERE AORTIC STENOSIS

EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA

BD Completes Acquisition of Critical Care from Edwards Lifesciences

FIRST ALL-FEMALE TAVI TRIAL SHOWS EXCELLENT OUTCOMES FOR WOMEN RECEIVING EDWARDS VALVES

FIVE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR FEMALE AND SMALL ANNULUS PATIENTS WITH EDWARDS TAVR

Edwards Lifesciences to Sell Critical Care to BD

LARGE, REAL-WORLD STUDIES DEMONSTRATE CONTINUED EXCELLENT OUTCOMES FOR PATIENTS RECEIVING EDWARDS SAPIEN TAVR

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards receives CE mark for tricuspid valve replacement

EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL

Call to Action

Post Category

Latest Posts

Social Links

SPECIAL THANKS TO OUR LEGACY & PLATINUM ELITE MEMBERS